Multifocal motor neuropathy: Current therapies and novel strategies

Drugs

Volumn 73, Issue 5, 2013, Pages 397-406

  Nobile Orazio, Eduardo ^a   Gallia, Francesca ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ECULIZUMAB; FINGOLIMOD; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAFAMSTAT MESILATE; PLACEBO; RITUXIMAB;

AMENORRHEA; ANTIBODY TITER; ARTICLE; AZOOSPERMIA; BLADDER CANCER; BLOOD AUTOTRANSFUSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; COMPLEMENT ACTIVATION; DEMYELINATING NEUROPATHY; DERMATOMYOSITIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GOLD STANDARD; HUMAN; HUMORAL IMMUNITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR NERVE CONDUCTION; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NERVE BLOCK; NERVE FIBER DEGENERATION; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SENSORY NERVE CONDUCTION; TREATMENT DURATION; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYNEUROPATHIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879454064     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0029-z     Document Type: Article

References (98)

1. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve. 2005;31:663-80.
2. Vlam L, van der Pol W-L, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48-58.
3. Roth G, Rohr J, Magistris MR, Ochsner F. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Eur Neurol. 1986;25:416-23.
4. Chad DA, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology. 1986;36:1260-3.
5. Parry GJ, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve. 1988;11:103-7.
6. Pestronk A, Cornblath DR, Ilyas A, et al. A treatable multi-focal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73-8.
7. van Schaik IN, Van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005;2:CD004429.
8. Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75:818-25.
9. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol. 1001;115:4-18.
10. Van den Berg-Vos RM, Franssen H, Wokke JHJ, et al. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin. Neurology. 2000;48:919-26.
11. Nobile-Orazio E, Gallia F, Terenghi F, et al. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci. 2008;266:156-63.
12. Gooch CL, Amato AA. Are anti-ganglioside antibodies of clinical value in multifocal motor neuropathy? Neurology. 2010;75:1950-1.
13. van Schaik IN, Bossuyt PMM, Brand A, Vermeulen M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta analysis. Neurology. 1995;45:1570-7.
14. Bech E, Andersen H, Orntoft TF, Jakobsen J. Association of IgM type anti-GM1 antibodies and muscle strength in chronic acquired demyelinating polyneuropathy. Ann Neurol. 1998;43:72-8.
15. Taylor BV, Gross LA, Windebank AJ. The sensitivity and specificity of anti-GM1 antibody testing. Neurology. 1996;47:951-5.
16. Arunachalam R, Osei-Lah A, Mills KR. Transcutaneous cervical root stimulation in the diagnosis of multifocal motor neuropathy with conduction block. J Neurol Neurosurg Psychiatry. 2003;74:1329-31.
17. Akaza M, Kanouchi T, Inaba A, et al. Motor nerve conduction study in cauda equina with high-voltage electrical stimulation in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve. 2011;43:274-82.
18. Deroide N, Uzenot D, Verscheuren A, et al. Triple-stimulation technique in multifocal motor neuropathy with conduction block. Muscle Nerve. 2007;35:632-6.
19. Nodera H, Bostock H, Yzumi Y, et al. Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test. Neurology. 2006;67:280-7.
20. Olney RK, Lewis RA, Putnam TD, Campellone JV. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve. 2003;27:117-21.
21. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society. First revision. J Peripher Nerv Syst. 2010;15:295-301.
22. Santoro M, Uncini A, Corbo M, et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol. 1992;31:385-90.
23. Uncini A, Santoro M, Corbo M, et al. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve. 1993;16:610-5.
24. Arasaki K, Kusunoki S, Kudo N, Kanazawa I. Acute conduction block in vitro following exposure to anti-ganglioside sera. Muscle Nerve. 1993;16:587-93.
25. Paparounas K, O'Hanlon GM, O'Leary CP, et al. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain. 1999;122:807-16.
26. Roberts M, Willison HJ, Vincent A, Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol. 1995;38:111-8.
27. Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology. 1992;42:506-9.
28. Charles N, Benoit P, Vial C, et al. Intravenous immunoglobulin treatment in multifocal motor neuropathy. Lancet. 1992;340:182.
29. Nobile-Orazio E, Meucci N, Barbieri S, et al. High dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology. 1993;43:537-44.
30. Kermode AG, Laing BA, Carroll WM, Mastaglia FL. Intravenous immunoglobulin for multifocal motor neuropathy. Lancet. 1992;340:920-1.
31. Chaudhry V, Corse A, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 1993;33:237-42.
32. Azulay J-P, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies. Neurology. 1994;44:429-32.
33. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;59:248-52.
34. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology. 2000;55:1257-62.
35. Léger J-M, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind placebo-controlled study. Brain. 2001;124:145-53.
36. Hahn AF, Beydoun SR, Lawson V, The IVIg in MMN Study Team, et al. A phase III randomized, placebo-controlled study of the efficacy and safety of 10 % liquid intravenous immunoglobulin (IVIg) for the treatment of multifocal motor neuropathy (abstract). J Peripher Nerv Syst. 2012;17:243-4.
37. Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain. 2002;125:1875-86.
38. Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in multifocal motor neuropathy? Neurology. 2004;62:666-8.
39. Léger JM, Viala K, Cancalon F, et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry. 2008;79:93-6.
40. Bauman A, Hess CW, Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol. 2009;256:608-14.
41. Van Asseldonk JTH, Van den Berg LH, Kalmijn S, et al. Axonal loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2006;77:743-7.
42. Vucic S, Black KR, Chong PS, Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology. 2004;63:1264-9.
43. Eftimov F, Vermeulen M, de Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009;14:93-100.
44. Harbo T, Andersen H, Jacobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology. 2010;75:1377-80.
45. Misbah SA, Baumann A, Fazio R, et al. A smooth transition protocol going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst. 2011;16:92-7.
46. Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized single-blinded cross-over trial. Eur J Neurol. 2009;16:631-8.
47. Cocito D, Serra G, Paolasso I, et al. Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies. J Peripher Nerv Sys. 2012;17:426-8.
48. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibodies and intravenous immunoglobulin for rheumatic diseases: rationale and mechanism of action. Nature Clin Pract Rheumatol. 2007;3:262-72.
49. Van den Berg LH, Franssen H, Wokke JHJ. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain. 1998;121:421-8.
50. Malik U, Oleksowicz L, Latov N, Cardo LJ. Intravenous γ-globulin inhibits binding of anti-GM1 on its target antigen. Ann Neurol. 1996;1996(39):136-9.
51. Piepers S, Jansen MD, Cats EA, et al. IVIg inhibits classical pathway activity and anti-GM1 IgM mediated complement deposition in MMN. J Neuroimmunol. 2010;229:256-62.
52. Yuki N, Watanabe H, Nakajima T, Späeth PJ. IVIg blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2011;82:87-91.
53. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778-83.
54. Lehman HC, Hoffmann FR, Fusshoeller A, et al. The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci. 2008;271:34-9.
55. Carpo M, Cappellari A, Mora G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology. 1998;50:1480-2.
56. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Sys. 2010;15:1-9.
57. Umapathi T, Hughes R, Nobile-Orazio E, Leger J. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev. 2012;4:CD003217.
58. Nobile-Orazio E, Gallia F, Tuccillo F, Terenghi F. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Curr Opin Neurol. 2010;23:519-23.
59. Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol. 1991;30:397-401.
60. Krarup C, Stewart JD, Sumner AJ, et al. A syndrome of asymmetric limb weakness with motor conduction block. Neurology. 1990;40:118-27.
61. Pringle CE, Belden J, Veitch JE, Brown WF. Multifocal motor neuropathy presenting as ophthalmoplegia. Muscle Nerve. 1997;20:347-51.
62. Axelson HW, Oberg G, Ashmark H. No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy. Acta Neurol Scand. 2008;117:432-4.
63. Meucci N, Cappellari A, Barbieri S, et al. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 1997;63:765-9.
64. Bouche P, Moulonguet A, Younes-Chennoufi AB, et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry. 1995;59:38-44.
65. Hausmanowa-Petrusewicz I, Rowisnka-Marcinska K, Kopec K. Chronic acquired demyelinating motor neuropathy. Acta Neurol Scand. 1991;84:40-5.
66. Nemni R, Santuccio G, Calabrese E, Galardi G, Canal N. Efficacy of cyclosporine treatment in multifocal motor neuropathy. J Neurol. 2003;250:1118-20.
67. Nobile-Orazio E, Terenghi F, Cocito D, et al. Oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy. J Peripher Nerv Syst. 2009;14:203-5.
68. Benedetti L, Grandis M, Nobbio L, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve. 2004;29:748-9.
69. Piepers S, Van den Berg-Vos R, Van der Pol W-L, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain. 2007;130:2004-10.
70. ®): a review of its use in the treatment of relapsing multiple sclerosis. Drugs. 2011;71(14):1865-91.
71. Weinstock-Guttman B, Ransohoff RM, Kinkel P, et al. The interferon: biological effects, mechanism of action and use in multiple sclerosis. Ann Neurol. 1995;37:7-15.
72. Martina ISJ, van Doorn PA, Schmitz PIM, et al. Chronic motor neuropathies: response to interferon-β1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry. 1999;66:197-201.
73. Van den Berg-Vos RM, Van den Berg LH, Franssen H, et al. Treatment of multifocal motor neuropathy with interferon-β1A. Neurology. 2000;54:1518-21.
74. Radziwill AJ, Botez S, Novy J, Kuntzer T. Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial. J Peripher Nerv Syst. 2009;14:201-2.
75. Dalakas MC. Inhibition of B cell functions: implications for neurology. Neurology. 2008;70:2252-60.
76. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70(11):1445-76.
77. Benedetti L, Briani C, Fazio R, et al. Rituximab in patients with CIDP: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82:306-8.
78. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286-93.
79. Pestronk A, Florence J, Miller T, et al. Treatment of IgM associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485-9.
80. Rojas-Garcia R, Gallardo E, de Andrés I, et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology. 2003;61:1814-6.
81. Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology. 2004;63:2178-9.
82. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007;35:66-9.
83. Stielgbauer K, Topakian R, Hinterberger G, Aichner FT. Beneficial effect of rituximab therapy in multifocal motor neuropathy. Neuromusc Disord. 2009;19:473-5.
84. ®) in multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15:196-201.
85. Michaud A, Delmont E, Jeandel PY, Desnuelle C. Improvement of severe and intravenous immunoglobulin-dependent multifocal motor neuropathy with conduction block after long-term ritxumab (in French). Rev Neurol (Paris). 2011;167:916-20.
86. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the research on adverse drug event and reports project. Blood. 2009;113:4834-40.
87. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256-64.
88. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;12:1233-43.
89. Fitzpatrick AM, Mann CA, Barry S, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16:84-91.
90. Qu H, Ricklin D, Lambris JD. Recent developments in low molecular weight complement inhibitors. Mol Immunol. 2009;47:185-95.
91. Phongsisay V, Susuki K, Matsuno K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome. J Neuroimmunol. 2008;205:101-4.
92. Schweighofer CD, Wendtner C-M. First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther. 2010;3:53-67.
93. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-801.
94. Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257:913-9.
95. Avivi I, Chakrabarti S, Kottaridis P, et al. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transpl. 2004;34:137-42.
96. Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25:673-98.
97. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion and memory. J Immunol. 2000;164:5761-70.
98. Zhang Z, Zhang Z-Y, Fauser U, et al. FTY720 ameliorates experimental autoimmmune neuritis by inhibition of lymphocytes and monocytes infiltration in peripheral nerves. Exp Neurol. 2008;210:681-90.